Clinical trialNCT01895452CompletedPhase 3Interventional

An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

SponsorAlkermes, Inc.Enrollment291Schizophrenia

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Robert Risinger, MD
Alkermes, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

57 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Bulgaria

Alkermes Investigational Site
Burgas, Bulgaria
Alkermes Investigational Site
Novi Iskar, Bulgaria
Alkermes Investigational Site
Pazardzhik, Bulgaria
Alkermes Investigational Site
Plovdiv, Bulgaria
Alkermes Investigational Site
Sofia, Bulgaria
Alkermes Investigational Site
Targovishte, Bulgaria
Alkermes Investigational Site
Veliko Tarnovo, Bulgaria
Alkermes Investigational Site
Vratsa, Bulgaria

Malaysia

Alkermes Investigational Site
Cheras, Malaysia
Alkermes Investigational Site
Johor Bahru, Malaysia
Alkermes Investigational Site
Kuala Lampur, Malaysia
Alkermes Investigational Site
Kuching, Malaysia

Philippines

Alkermes Investigational Site
Mariveles, Bataan, Philippines
Alkermes Investigational Site
Cebu City, Philippines
Alkermes Investigational Site
Iloilo City, Philippines
Alkermes Investigational Site
Mandaluyong, Philippines
Alkermes Investigational Site
Manila, Philippines

Romania

Alkermes Investigational Site
Bucharest, Romania
Alkermes Investigational Site
Oradea, Romania
Alkermes Investigational Site
Târgu Mureş, Romania

Russia

Alkermes Investigational Site
Roshchino, Vyborgskiy, Russia
Alkermes Investigational Site
Lipetsk, Russia
Alkermes Investigational Site
Moscow, Russia
Alkermes Investigational Site
Rostov-on-Don, Russia
Alkermes Investigational Site
Saint Petersburg, Russia
Roshchino Township
Samara, Russia
Roshchino Township
Saratov, Russia
Alkermes Investigational Site
Stavropol, Russia
Alkermes Investigational Site
Talagi, Russia
Alkermes Investigational Site
Yaroslavl, Russia

South Korea

Alkermes Investigational Site
Jeollanam-do, South Korea

Ukraine

Alkermes Investigational Site
Chernihiv, Ukraine
Alkermes Investigational Site
Donetsk, Ukraine
Alkermes Investigational Site
Kharkiv, Ukraine
Alkermes Investigational Site
Kherson, Ukraine
Alkermes Investigational Site
Kyiv, Ukraine
Alkermes Investigational Site
Lviv, Ukraine
Alkermes Investigational Site
Poltava, Ukraine
Alkermes Investigational Site
Ternopil, Ukraine
Roshchino Township
Vinnytsia, Ukraine

17 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jul 2013
Primary completion: 30 Jun 2016
Completion: 30 Jun 2016
Last update posted: 25 Aug 2017
Registered enrollment: 291
Registry id: NCT01895452

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.